[1] FU P.Association of dyslipidemia with the development and progression of type 2 diabetes[J]. Journal of Luzhou Medical College(西南医科大学学报), 2018,4(3):287-290 [2] RIDDERSTRÅLE M, ROSENSTOCK J, ANDERSEN KR, et al. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial[J].Diabetes Obes Metab, 2018, 20(12): 2768-2777. [3] MÜLLER-WIELAND D, KELLERER M, CYPRYK K, et al.Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2018, 20(11): 2598-2607. [4] QIAN D, TAN XP, MEI ZR, et al.Efficacy and safety of dipeptidyl peptidase-4 inhibitors combined with sulfonylureas in type 2 diabetes mellitus :a Meta-analysis[J]. Chongqing Medicine(重庆医学), 2019, 48(16): 2814-2821. [5] YE LH, HE M, ZHAO XQ, et al.Research progress of potential drug interactions of sulfonylureas[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2018, 38(12): 1333-1337. [6] MOKTA JK, RAMESH, SAHAI AK, et al.Comparison of safety and efficacy of glimepiride-metformin and vildagliptin- metformin treatment in newly diagnosed type 2 diabetic patients[J]. J Assoc Physicians India, 2018, 66(8): 30-35. [7] HOLLANDER P, HILL J, Johnson J, et al.Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin[J]. Curr Med Res Opin, 2019, 35(8): 1335-1343. [8] GAO JR, LI Y, LUO H, et al.Analysis of adverse reactions/events of glimepiride based on case reports[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2015, 35(13): 1231-1233. [9] BAJAJ S.RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017[J]. Int J Diabetes Dev Ctries, 2018, 38(Suppl 1): 1-115. [10] National Center for ADR Monitoring,China. Technical specifications and evaluation criteria of common severe adverse drug reactions(常见严重药品不良反应技术规范及评价标准)[S]. 2011. [11] WANG YM, WANG GJ, ZHANG SL, et al.Adverse drug reactions of antidiabetic drugs and the preventive strategies[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2015, 35(24): 2233-2236. [12] LI F, LIU ZG.Analysis report on 425 cases of adverse reactions of hypoglycemic drugs[J]. Shanxi Medical Journal(山西医药杂志), 2018, 47(14): 1715-1717. [13] YI P.Analysis of adverse reactions of sulfonylureas and study on rational drug use[J]. Chinese Journal of Critical Care Medicine(中国急救医学),2017,37(z2):36-37. [14] China food and drug administration.2015 national adverse drug reaction monitoring annual report(2015年国家药品不良反应监测年度报告)[EB/OL].(2016-07-13)[2019-12-30].https://www.doc88.com/p-2485232561901.html. [15] SHU B, LIU YL, Jiang L.Research progress of evaluation criteria for potential inappropriate drug use in the elderly[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2019, 39(18): 1905-1910. [16] ZHANG XL, ZHOU S, ZHOU Y, et al.Research progress in inappropriate drug use in the elderly[J]. Chinese Journal of Geriatrics(中华老年医学杂志), 2018, 37(4): 479-484. [17] KONG YX, DONG AM, ZHENG JT, et al.Hypoglycemia and its influential factors in outpatients with type 2 diabetes mellitus[J].Chinese General Practice(中国全科医学), 2019, 2(8): 936-941. [18] CHEN CM, WANG G.Exploring the influence of extrapancreatic effect of sulphonylureas on clinical outcomes in patients with type 2 diabetes[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2019, 35(1): 76-80. [19] TERAUCHI Y, YAMADA Y, ISHIDA H, et al.Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial)[J].Diabetes Obes Metab, 2017, 19(8): 1188-1192. [20] BIESSELS GJ, JANSSEN J, VAN DEN BERG E, et al. Rationale and design of the CAROLINA® - cognition substudy:a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus[J]. BMC Neurol, 2018, 18(1): 7. |